|My mid-year synopsis of GERN - 2018
INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
GERN (market cap is $0.594B was $0.287B)
Geron is a leading edge biotechnology firm developing a cancer vaccine treatment based on managing telomerase. Their most advanced treatment is addressing blood disorders. As with other cancer vaccines, the first treatment approved may be sufficient for profitability, but the upside is amplified if the same technology can be applied to other cancers. Currently, Geron is in phase 2 / 3 clinical trials. If successful, the treatment must still be approved by the FDA before becoming publicly available. Each positive step closer decreases the risk to the company and the risk discount to the stock.
Pardon the copy and paste from another, similar, and associated company (Asterias, AST), but the same statements apply.
“A major caution with innovative biotechnology companies and their treatments is that the FDA is not as innovative in its approval process. … Unless the FDA decides to accelerate the process on compassionate grounds, public treatments and subsequent profits are many years away.”
DISCLOSURE LTBH since 1999 and continuing to hold. I might consider buying more, but will probably wait for substantial, quantitative results are made public - which would spark a spike that might price me out of the sale. Stay tuned.
(I've also collected links to the other discussion boards and my other stocks over on my blog trimbathcreative.wordpress.com